Skip to main content
Premium Trial:

Request an Annual Quote

US Genomics Pens MicroRNAs Agreement With Lahey Clinic to Study Urologic Cancer

NEW YORK (GenomeWeb News) — US Genomics has signed an agreement with the Lahey Clinic to look at microRNAs and the development of urologic cancers, the company said today.
The company said that the Lahey Clinic will use US Genomics’ Trilogy 2020 molecule detection platform and its Direct miRNA assay to “develop more accurate prognoses” for patients suffering from bladder cancer and prostate cancer.
Lahey Clinic urologist John Libertino adds that this agreement should help develop diagnostics used for “several major urologic cancers.”
Financial terms of the agreement were not disclosed.